Longeveron (LGVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 May, 2026Executive summary
The annual meeting will be held virtually on July 1, 2026, with voting available online, by phone, or by mail.
Stockholders will vote on six key proposals, including director elections, amendments to the certificate of incorporation, incentive plan changes, auditor ratification, and potential adjournment.
The record date for voting eligibility is May 11, 2026.
Proxy materials are distributed primarily via internet, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting.
Approval to increase authorized Class A common stock from 84,295,000 to 175,000,000 shares.
Approval to effect a reverse stock split at a ratio between 1:2 and 1:20, at the Board's discretion.
Amendment to the 2021 Incentive Award Plan to add 5,000,000 shares for a total of 10,657,440 shares.
Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year 2026.
Approval to adjourn the meeting if more time is needed to solicit votes for the share increase or reverse split.
Board of directors and corporate governance
The Board is divided into three classes, with five current directors and three nominees for election.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Strategy.
Majority of the Board is independent; executive sessions are held without management.
Board leadership combines the roles of Executive Chairman and Chief Science Officer.
Directors receive annual retainers, committee fees, and equity awards; temporary fee reductions were implemented and later restored.
Latest events from Longeveron
- HLHS Phase 2b data and PRV eligibility position laromestrocel for major value inflection.LGVN
Investor presentation4 May 2026 - Biotech registers resale of shares amid financial uncertainty and ongoing clinical development.LGVN
Registration filing10 Apr 2026 - Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications.LGVN
Investor presentation1 Apr 2026 - Positive clinical progress in stem cell therapies for rare and aging-related diseases.LGVN
Investor presentation18 Mar 2026 - $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses.LGVN
Q4 202517 Mar 2026 - Vote sought on reverse stock split to maintain Nasdaq listing and enhance share value.LGVN
Proxy Filing3 Mar 2026 - Directors elected, incentive plan amended, and auditors ratified; results to be filed.LGVN
AGM 20243 Feb 2026 - Revenue and cash up, net loss down, and FDA designations boost growth outlook.LGVN
Q2 20242 Feb 2026 - Revenue up 177%, pivotal trials advanced, and cash runway extends through Q4 2025.LGVN
Q3 202414 Jan 2026